Vor Biopharma Inc reports results for the quarter ended in March - Earnings Summary

Vor Biopharma

11/05/2023 22:17

* Vor Biopharma Inc  VOR.OQ  reported a quarterly adjusted
loss
of 43 cents​​ per share for the quarter ended in March. The mean
expectation of eight analysts for the quarter was for a loss
of 38 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Vor Biopharma Inc's reported EPS for the quarter was a
loss
of 43 cents​.
    * The mean earnings estimate of analysts had risen by
about 29.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Vor Biopharma Inc shares had fallen by 24.0% this
quarter and
lost 38.5% so far this year.
    * The company reported a quarterly loss of $28.43 million.
    * Wall Street's median 12-month price target for Vor
Biopharma Inc
is $16.75 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 09:17 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.38          -0.43          Missed
 Dec. 31 2022      -0.60          -0.52          Beat
 Sep. 30 2022      -0.61          -0.63          Missed
 Jun. 30 2022      -0.66          -0.58          Beat